Jan

    Biosimilars: Policy Developments and Emerging Competition Issues

    12 PM EST

    This program will address recent developments relating to the unique challenges that follow-on biologics (also known as biosimilars) present for regulators, policymakers, and drugmakers.  While biosimilars are not yet available in the U.S. market, sales have begun in Europe.  Among other things, this panel will discuss Europe's experience with biosimilars and the implications that the European experience has for U.S. regulation and sales of biosimilars, expected to begin in 2015.  

    Moderator: 

    * Amanda G. Lewis, Federal Trade Commission

    Speakers:

    * Susan DeSanti, Federal Trade Commission
    * Alexander Roediger, MSD (Europe) Inc.
    * Maria Salgado, Cornerstone Research
    * Darren Tucker, Bingham McCutchen


    FREE:  Antitrust Section Members, Government, Non-Profit Employees and Students
    $25.00:  Other Non-Members
     
    Learn about Section Membership or call 800-285-2221 to join with source code:  RAT14IP25.  Instructions for accessing the live program will be provided in an confirmation email.  For this and all upcoming events visit:  http://AmBar.orjg/ATEvents.

    CLE
    The ABA is not seeking CLE credit for this program.

    Audio Archive
    Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

     

     

     

    $25
    NON-MEMBERS
    $10
    MEMBERS
    $0
    SECTION MEMBERS
    Register Now *Additional discounts may apply at checkout

    Log In to view your rate

    Biosimilars: Policy Developments and Emerging Competition Issues

    Event Details

    Format

    Teleconference

    Date

    Jan 12, 2015

    2015-01-12T12:00:00-05:00 2015-01-12T13:30:00-05:00 Biosimilars: Policy Developments and Emerging Competition Issues

    This program will address recent developments relating to the unique challenges that follow-on biologics (also known as biosimilars) present for regulators, policymakers, and drugmakers.  While biosimilars are not yet available in the U.S. market, sales have begun in Europe.  Among other things, this panel will discuss Europe's experience with biosimilars and the implications that the European experience has for U.S. regulation and sales of biosimilars, expected to begin in 2015.  

    Moderator: 

    * Amanda G. Lewis, Federal Trade Commission

    Speakers:

    * Susan DeSanti, Federal Trade Commission
    * Alexander Roediger, MSD (Europe) Inc.
    * Maria Salgado, Cornerstone Research
    * Darren Tucker, Bingham McCutchen


    FREE:  Antitrust Section Members, Government, Non-Profit Employees and Students
    $25.00:  Other Non-Members
     
    Learn about Section Membership or call 800-285-2221 to join with source code:  RAT14IP25.  Instructions for accessing the live program will be provided in an confirmation email.  For this and all upcoming events visit:  http://AmBar.orjg/ATEvents.

    CLE
    The ABA is not seeking CLE credit for this program.

    Audio Archive
    Provided all releases are obtained, MP3 recordings of this program will be available to Section members on the Committee Program Audio page.

     

     

     

    Sponsors

    Section of Antitrust Law

    Related Products

    Related On-Demand CLE